Navigation Links
Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management
Date:5/28/2009

LYONS, France, May 28 /PRNewswire/ -- Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies.

Its pipeline consists only of innovative projects with new mechanisms of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies.

Poxel has secured several programs from the Merck Serono pipeline. These include a first-in-class project, Imeglimin -which has already achieved its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from the Research until close to clinical development stages.

Poxel's management is composed of a tight and seasoned team of professionals who previously led the Merck Serono diabetes franchise from Research to Clinical & Commercialization. They have a proven track record in the pharmaceutical industry and extensive skills both in project management and technical expertise. The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the complete product life cycle.

Poxel's team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on cardio-metabolic diseases.

A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets.

All this provides Poxel with a significant competitive advantage.

Poxel's team will be advised by a highly regarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe.

Poxel will start the development of its core assets, while seeking funding in order to create additional value from its unique pipeline. Neither Merck KGaA nor Merck Serono is shareholders of Poxel.

About Type 2 Diabetes:

Type 2 Diabetes is defined by a failure of sensitive tissues to respond to insulin, a hormone involved in glucose and fatty acid metabolism, Type 2 diabetes hence being known as non-insulin-dependent diabetes. 90% of diabetic patients in the world suffer from type 2 diabetes.

In 2007, more than 220 million people suffered from Type 2 diabetes worldwide, including over 65 million patients in the US and Europe. It is predicted that more than 300 million patients will have this disease by 2025 (IDF).

The market is about EUR bn9.6 turnover in 2007, expected to reach EUR bn15 by 2016.

Existing therapies on the market are dominated by few dominant product classes, but significant unmet needs remain.

About Poxel:

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical companies. Poxel will further develop its portfolio by considering all opportunities corresponding to its core domain of competencies.

Visit Poxel's website: http://www.poxelpharma.com


'/>"/>
SOURCE Poxel SAS
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
2. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
3. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
4. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
5. Opus Environmental Introduces Innovative Food Waste Elimination Equipment to U.S. Food Industry
6. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
7. GSK and Pfizer Innovative Agreement Creates Specialist HIV Company
8. Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity
9. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
10. FasterCures Rewards Two InnoCentive Solvers for Innovative Ideas to Accelerate Medical Research
11. Prous Institute Presents Innovative Approach to Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... KY and San Diego, CA (PRWEB) , ... April 29, 2016 ... ... National Stem Cell Foundation (NSCF) to support the development of a patient-specific stem cell ... Dr. Andrés Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research ...
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
(Date:4/28/2016)... ... 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), a division ... its Maple Grove, Minnesota technical center, May 11-12. The event will feature ... 20 leading suppliers of tooling, accessories, software and other related technology will participate ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, ... Plus® to offer Oncimmune,s Early CDT®-Lung, a blood ... detection of lung cancer Early CDT®-Lung test ... individuals. --> Early CDT®-Lung test to its ... --> Oncimmune, a leader in early cancer detection, ...
Breaking Biology News(10 mins):